![Piero di Lorenzo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Piero di Lorenzo is the founder of IRBM SpA.
He held the titles of Chairman and Chief Executive Officer at the company.
Aktive Positionen von Piero di Lorenzo
Unternehmen | Position | Beginn |
---|---|---|
IRBM SpA
![]() IRBM SpA BiotechnologyHealth Technology IRBM SpA is a research organization that specializes in drug discovery and development. IRBM is based in Pomezia, IT, and has subsidiaries in Italy. The Italian company produces recombinant proteins in a homogeneous state and use cyclization to pre-organize compounds for target binding. The private company uses nuclear magnetic resonance (NMR) spectroscopy to study structural biology, clinical research solutions, functional genomics, structure/activity relationships, drug discovery, macromolecule, and small-molecule analysis. The company has a screening library of over 320,000 compounds and use virtual screening and NMR to drive innovation. The company was founded in 2010 by Piero di Lorenzo, who has been the CEO since then. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
IRBM SpA
![]() IRBM SpA BiotechnologyHealth Technology IRBM SpA is a research organization that specializes in drug discovery and development. IRBM is based in Pomezia, IT, and has subsidiaries in Italy. The Italian company produces recombinant proteins in a homogeneous state and use cyclization to pre-organize compounds for target binding. The private company uses nuclear magnetic resonance (NMR) spectroscopy to study structural biology, clinical research solutions, functional genomics, structure/activity relationships, drug discovery, macromolecule, and small-molecule analysis. The company has a screening library of over 320,000 compounds and use virtual screening and NMR to drive innovation. The company was founded in 2010 by Piero di Lorenzo, who has been the CEO since then. | Health Technology |